Zelie Bailes
Overview
Explore the profile of Zelie Bailes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oppenheimer J, Hanania N, Chaudhuri R, Sagara H, Bailes Z, Fowler A, et al.
Chest
. 2023 Jun;
164(5):1087-1096.
PMID: 37385337
Background: Studies examining agreement between home and clinic spirometry in patients with asthma are limited, with conflicting results. Understanding the strengths and limitations of telehealth and home spirometry is particularly...
2.
Tabberer M, von Maltzahn R, Bacci E, Karn H, Hsieh R, Howell T, et al.
J Patient Rep Outcomes
. 2021 Oct;
5(1):104.
PMID: 34632556
Background: Symptom constructs included in the Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS®: COPD) tool may be relevant to patients with asthma. The purpose of this study was...
3.
Lee L, Bailes Z, Barnes N, Boulet L, Edwards D, Fowler A, et al.
Lancet Respir Med
. 2020 Sep;
9(1):69-84.
PMID: 32918892
Background: Despite inhaled corticosteroid plus long-acting β-agonist (ICS/LABA) therapy, 30-50% of patients with moderate or severe asthma remain inadequately controlled. We investigated the safety and efficacy of single-inhaler fluticasone furoate...
4.
Kerwin E, Pascoe S, Bailes Z, Nathan R, Bernstein D, Dahl R, et al.
Respir Res
. 2020 Jun;
21(1):148.
PMID: 32532275
Background: Patients with asthma uncontrolled on inhaled corticosteroids may benefit from umeclidinium (UMEC), a long-acting muscarinic antagonist. Methods: This Phase IIb, double-blind study included patients with reversible, uncontrolled/partially-controlled asthma for...
5.
Ma R, Del Prato S, Gallwitz B, K Shivane V, Lewis-DAgostino D, Bailes Z, et al.
J Diabetes Investig
. 2017 Sep;
PMID: 28921919
Aims/introduction: Type 2 diabetes mellitus is an epidemic in Asia, yet clinical trials of glucose-lowering therapies often enroll predominantly Western populations. We explored the initial combination of metformin and linagliptin,...
6.
Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia
Ross S, Caballero A, Del Prato S, Gallwitz B, Lewis-DAgostino D, Bailes Z, et al.
Postgrad Med
. 2016 Sep;
128(8):747-754.
PMID: 27684308
Objectives: Few studies of oral glucose-lowering drugs exist in newly diagnosed type 2 diabetes (T2D) patients with marked hyperglycemia, and insulin is often proposed as initial treatment. We evaluated the...
7.
Taniguchi H, Xu Z, Azuma A, Inoue Y, Li H, Fujimoto T, et al.
Respirology
. 2016 Jul;
21(8):1425-1430.
PMID: 27399197
Background And Objective: In the two-replicate randomized Phase III INPULSIS® trials in patients with idiopathic pulmonary fibrosis (IPF), nintedanib 150 mg bd significantly reduced the annual rate of decline in...
8.
Richeldi L, Cottin V, du Bois R, Selman M, Kimura T, Bailes Z, et al.
Respir Med
. 2016 Feb;
113:74-9.
PMID: 26915984
Background And Purpose: The Phase II TOMORROW trial and two Phase III INPULSIS(®) trials investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic pulmonary fibrosis (IPF)....
9.
Ji L, Zinman B, Patel S, Ji J, Bailes Z, Thiemann S, et al.
Adv Ther
. 2015 Mar;
32(3):201-15.
PMID: 25805187
Introduction: The aim of this study was to investigate the efficacy and safety of linagliptin + low-dose (LD) metformin once daily versus high-dose (HD) metformin twice daily in treatment-naïve patients...